Price Alert

PTC Therapeutics Inc. (PTCT)

NASDAQ: PTCT · Real-Time Price · USD

48.16

-0.54 (-1.11%)

At close: Aug 15, 2025, 9:53 AM

-1.11% (1D)

Bid	48
Market Cap	3.83B
Revenue (ttm)	1.77B
Net Income (ttm)	594.84M
EPS (ttm)	7.05
PE Ratio (ttm)	6.83
Forward PE	-19.02
Analyst	Buy

Ask	48.54
Volume	81,453
Avg. Volume (20D)	1,119,585
Open	48.86
Previous Close	48.70
Day's Range	48.12 - 49.01
52-Week Range	30.41 - 58.38
Beta	0.54

About PTCT

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol PTCT

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for PTCT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

PTC Therapeutics has released their quartely earnings on Aug 7, 2025:

Revenue of $178.88M exceeds estimates by $6.19M, with -4.19% YoY decline.

EPS of -0.83 exceeds estimates by 0.24, with 35.66% YoY growth.

Next Earnings Release

PTC Therapeutics Inc. is scheduled to release its earnings on Nov 6, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

6 days ago

-9.89%

PTC Therapeutics shares are trading lower after th... Unlock content with Pro Subscription

2 weeks ago

+11.16%

PTC Therapeutics shares are trading higher after the company announced it has gained FDA approval for SEPHIENCE.

News

1 week ago · seekingalpha.com

PTC Therapeutics, Inc. (PTCT) Q2 2025 Earnings Call Transcript

PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Ellen Cavaleri - Corporate Participant Eric Pauwels - Chief Business Officer Jarwe...

1 week ago · zacks.com

PTC Therapeutics (PTCT) Reports Q2 Earnings: What Key Metrics Have to Say

The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street ...

1 week ago · fool.com

PTCT Earnings Beat but Sales Drop 4%

1 week ago · zacks.com

PTC Therapeutics (PTCT) Reports Q2 Loss, Beats Revenue Estimates

PTC Therapeutics (PTCT) came out with a quarterly loss of $0.83 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to a loss of $1.16 per share a year ago.

2 weeks ago · zacks.com

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago · zacks.com

PTC Therapeutics (PTCT) Surges 11.2%: Is This an Indication of Further Gains?

PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more st...

2 weeks ago · benzinga.com

Sephience Gets FDA Approval, Now A Key Revenue Driver For PTC Therapeutics

The U.S. Food and Drug Administration approved on Monday PTC Therapeutics, Inc.'s PTCT SEPHIENCE (sepiapterin) for children and adult patients with phenylketonuria (PKU).

2 weeks ago · benzinga.com

These Analysts Increase Their Forecasts On PTC Therapeutics

PTC Therapeutics, Inc. PTCT announced it has gained FDA approval for SEPHIENCE on Monday.

2 weeks ago · reuters.com

US FDA approves PTC Therapeutics' metabolic disorder drug

The U.S. Food and Drug Administration has approved PTC Therapeutics' oral drug to treat a rare inherited metabolic disorder that prevents the body from properly breaking down certain amino acids, the ...

1 month ago · businesswire.com

PTCT Investors Have Opportunity to Join PTC Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)---- $PTCT--PTCT Investors Have Opportunity to Join PTC Therapeutics, Inc. Fraud Investigation with the Schall Law Firm.

Load More News